← Russell 3000 cross-section

CAH CARDINAL HEALTH INC

Trailing twelve months to 2025-12-31 · as filed 2026-02-05, not restated
Consumer Staples

Scale

Market cap
$54.6bn
Revenue TTM
$244.7bn
Net income TTM
$1.7bn
Free cash flow
$5.5bn
Composite score
70.6
Sector rank
#225

Valuation

P / E
32.8
EV / EBITDA
15.2
EV / sales
0.2
FCF yield
10.09%
Earnings yield vs 10-yr
-1.69pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
0.7%
EBITDA margin
1.4%
ROE
-57.6%
ROIC
Revenue growth
10.1%

Insider activity, last 90 days

Net open-market
$-59.55m
Buyers
0
Sellers
7

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Overview of Consolidated Results Revenue Revenue for the three months ended March 31, 2026 increased 11 percent to $60.9 billion from the comparative prior-year quarter, primarily due to branded and specialty pharmaceutical sales growth from existing customers. Revenue for the nine months ended March 31, 2026 increased 17 percent to $190.6 billion from the comparative prior-year period, primarily due to branded and specialty pharmaceutical sales growth from existing and new customers. GAAP operating earnings for the three and nine months ended March 31, 2026 decreased 30 percent to $509 million and increased 2 percent to $1.9 billion from the comparative prior-year periods, respectively. …CARDINAL HEALTH INC, 10-Q, period ended 2026-03-31, filed 2026-04-30

Read the full passage →